Craig Hunsaker Sells 82,765 Shares of Alphatec (NASDAQ:ATEC) Stock

Key Points

• EVP Craig Hunsaker sold 82,765 shares on March 9 at an average price of $12.45 for a total of $1,030,424.25, leaving him with 1,726,209 shares — a 4.58% decrease in his ownership.
• Alphatec beat expectations with $0.06 EPS (vs. $0.04 est.) and revenue of $212.93M, up 20.4% year‑over‑year, and analysts hold a consensus "Moderate Buy" with an average price target of $22.82.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig Hunsaker sold 82,765 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the transaction, the executive vice president directly owned 1,726,209 shares of the company's stock, valued at approximately $21,491,302.05. This trade represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Alphatec Price Performance

Alphatec stock traded down $0.36 during midday trading on Tuesday, reaching $12.51. 2,228,465 shares of the company were exchanged, compared to its average volume of 3,318,480. Alphatec Holdings, Inc. has a 1 year low of $8.81 and a 1 year high of $23.29. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -13.17 and a beta of 1.02. The firm's 50-day simple moving average is $15.78 and its 200-day simple moving average is $16.99. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. The firm had revenue of $212.93 million during the quarter, compared to analyst estimates of $212.67 million. Alphatec's revenue was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) EPS. On average, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Barclays lifted their price target on shares of Alphatec from $23.00 to $27.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 7th. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a report on Saturday, January 31st. Lake Street Capital reaffirmed a "buy" rating on shares of Alphatec in a research report on Wednesday, February 25th. Morgan Stanley set a $23.00 target price on shares of Alphatec in a research report on Tuesday, December 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Alphatec in a report on Monday, January 12th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $22.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its stake in shares of Alphatec by 292.2% in the 4th quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company's stock valued at $46,834,000 after purchasing an additional 1,658,349 shares in the last quarter. Granite Investment Partners LLC boosted its position in shares of Alphatec by 320.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company's stock worth $19,102,000 after purchasing an additional 1,311,748 shares in the last quarter. Iron Triangle Partners LP acquired a new stake in Alphatec in the 4th quarter valued at $27,051,000. Morgan Stanley boosted its stake in Alphatec by 22.0% during the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company's stock valued at $91,333,000 after purchasing an additional 784,191 shares during the last quarter. Finally, Tudor Investment Corp ET AL grew its stake in shares of Alphatec by 608.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company's stock worth $13,093,000 after acquiring an additional 773,367 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.